199 related articles for article (PubMed ID: 33120082)
1. Eligibility of real-world patients with metastatic breast cancer for clinical trials.
Batra A; Kong S; Cheung WY
Breast; 2020 Dec; 54():171-178. PubMed ID: 33120082
[TBL] [Abstract][Full Text] [Related]
2. Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials.
Batra A; Kong S; Cheung WY
Clin Colorectal Cancer; 2020 Dec; 19(4):e226-e234. PubMed ID: 32636076
[TBL] [Abstract][Full Text] [Related]
3. Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World.
Karim S; Xu Y; Kong S; Abdel-Rahman O; Quan ML; Cheung WY
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):e160-e166. PubMed ID: 31133363
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
[TBL] [Abstract][Full Text] [Related]
6. Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials.
Kaur M; Frahm F; Lu Y; Ascha MS; Guadamuz JS; Dotan E; Gottesman AS; Leybovich BC; Sondhi A; Zhao Y; Meropol NJ; Royce TJ
NEJM Evid; 2024 Apr; 3(4):EVIDoa2300236. PubMed ID: 38771994
[TBL] [Abstract][Full Text] [Related]
7. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.
Chari A; Romanus D; Palumbo A; Blazer M; Farrelly E; Raju A; Huang H; Richardson P
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):8-17.e16. PubMed ID: 31722839
[TBL] [Abstract][Full Text] [Related]
8. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
[TBL] [Abstract][Full Text] [Related]
9. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
10. Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
Berden FA; de Knegt RJ; Blokzijl H; Kuiken SD; van Erpecum KJ; Willemse SB; den Hollander J; van Vonderen MG; Friederich P; van Hoek B; van Nieuwkerk CM; Drenth JP; Kievit W
PLoS One; 2016; 11(9):e0161821. PubMed ID: 27598789
[TBL] [Abstract][Full Text] [Related]
11. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
13. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
14. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Rugo HS; Dieras V; Cortes J; Patt D; Wildiers H; O'Shaughnessy J; Zamora E; Yardley DA; Carter GC; Sheffield KM; Li L; Andre VAM; Li XI; Frenzel M; Huang YJ; Dickler MN; Tolaney SM
Breast Cancer Res Treat; 2020 Nov; 184(1):161-172. PubMed ID: 32789591
[TBL] [Abstract][Full Text] [Related]
15. Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'.
Jeremias A; Ruisi CP; Kirtane AJ; Lee T; Sylvia B; Pinto DS; Ho KK; Cutlip DE; Carrozza JP; Cohen DJ
Coron Artery Dis; 2008 Mar; 19(2):111-5. PubMed ID: 18300748
[TBL] [Abstract][Full Text] [Related]
16. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
17. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316).
Javid SH; Unger JM; Gralow JR; Moinpour CM; Wozniak AJ; Goodwin JW; Lara PN; Williams PA; Hutchins LF; Gotay CC; Albain KS
Oncologist; 2012; 17(9):1180-90. PubMed ID: 22723506
[TBL] [Abstract][Full Text] [Related]
18. Stratification and management of patients ineligible for lung cancer screening.
Aggarwal R; Lam AC; Huang J; Hueniken K; Nguyen D; Khan K; Shaikh T; Shepherd FA; Tsao MS; Xu W; Kavanagh J; Liu G
Respir Med; 2021 Nov; 188():106610. PubMed ID: 34592536
[TBL] [Abstract][Full Text] [Related]
19. Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation.
Unger JM; Hershman DL; Fleury ME; Vaidya R
JAMA Oncol; 2019 Mar; 5(3):326-333. PubMed ID: 30629092
[TBL] [Abstract][Full Text] [Related]
20. Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma: A Population-based Study.
Tsang ES; Davies JM; Loree JM; Lim HJ; Renouf DJ; Gill S
Am J Clin Oncol; 2020 Nov; 43(11):788-791. PubMed ID: 32868523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]